<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00537732</url>
  </required_header>
  <id_info>
    <org_study_id>IKP-219</org_study_id>
    <secondary_id>2006-004650-24</secondary_id>
    <nct_id>NCT00537732</nct_id>
  </id_info>
  <brief_title>Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing</brief_title>
  <acronym>GERD</acronym>
  <official_title>Omeprazole and Reflux Disease - Improvement of Clinical Outcome by Genotype-adjusted Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Matthias Schwab</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Robert Bosch Gesellschaft für Medizinische Forschung mbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with gastroesophageal reflux disease (GERD) are either treated for 4 weeks with a
      standard dose (20mg) of omeprazole, a drug of first choice, or by an individualized dosing
      (20 or 60mg/day) according how fast the patient can metabolize (eliminate) the drug. The
      individual elimination capacity is genetically controlled and therefore all patients will be
      genotyped prior to therapy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment problems
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endoscopic healing rate in patients with GERD after 4 weeks of individualised dosing of omeprazole (according to metabolic capacity of the patient)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical healing rate in patients with GERD after 4 weeks of individualised dosing of omeprazole</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 tablets, only 20 mg omeprazole, genotype independent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 vs. 60 mg daily, genotype dependent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>20 mg daily</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omeprazole</intervention_name>
    <description>20 vs. 60 mg daily, genotype dependent</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with GERD grade A and B (mild to moderate severe disease) diagnosed by
             routine endoscopy will be recruited in different clinical and ambulant centres of
             gastroenterology; written informed consent is obligatory

          -  Range of Age: 20-70

          -  BMI: 20-30

        Exclusion Criteria:

          -  Patients who are allergic to proton-pump inhibitors or show incompatibility

          -  Patients who have lactase deficiency

          -  Patients who have severe chronic disease

          -  Patients who participated in another study during the last three months

          -  Patients who are pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Schwab, Prof, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Württemberg</state>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):2-8. Review.</citation>
    <PMID>15245569</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2007</study_first_submitted>
  <study_first_submitted_qc>September 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 1, 2007</study_first_posted>
  <last_update_submitted>February 24, 2014</last_update_submitted>
  <last_update_submitted_qc>February 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Robert Bosch Gesellschaft für Medizinische Forschung mbH</investigator_affiliation>
    <investigator_full_name>Matthias Schwab</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>gastro-oesophageal reflux disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

